PM Narendra Modi, industrialist Ratan Tata, biotech pioneer Raj Bhan, and mathematician Srinivasa Ramanujan. Gates recalls ...

Fortress Biotech (FBIO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.53 per share a year ago. These figures are ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds against a vast library of human genes in order to come up with new therapies.

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...

At the core of this agreement is a novel biocontrol product, based on the proprietary strain B2017 of Pseudomonas alloputida.

Even still, the pharma deals announced out of the event brought a clear message for the biotech industry. Technology ...

Leaders across the political spectrum want America to be the global leader in advanced manufacturing—both to strengthen ...

Vytrus Biotech unveils a revolutionary concept inspired by nature’s resilience to enhance skin longevity and radiance. Join ...

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Thursday, April 3rd, IPO Scoop reports. The company plans to issue 2,700,000 shares at ...